TriSalus Life Sciences Inc. Warrant (TLSIW)
Stock · NASDAQ · Health Care
$0.88as of 10/16/2026
Price chart
TLSIW Signal Track Record
How signals performed across all stocks →What TLSIW's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 22 | -17.3% | 27% | September 29, 2026 |
| Bollinger Band Breakdown | 20 | +5.9% | 60% | May 13, 2026 |
| Volume Spike | 11 | +1.0% | 55% | July 28, 2025 |
| 200-Day Moving Average TouchActive now | 10 | +2.4% | 70% | March 17, 2026 |
| Any 20-session window (baseline) | -1.3% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TLSIW
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization an…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 102
Fundamentals
- 1-day range
- $0.6951$0.9399
- Market cap
- $101.95M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- 1.86
- Avg. volume
- 2.2K
TriSalus Life Sciences Inc. Warrant Competitors
Chosen by industry and closest market cap.
- TLSIWTriSalus Life Sciences Inc. Warrant$0.8799▼ 2.23%Market cap $101.95MP/E —$0.4405$1.85
- KEQUKewaunee Scientific Corporation Common Stock$32.93▲ 2.30%Market cap $108.73MP/E 11.26$32$46.57
- BNRBurning Rock Biotech Limited American Depositary Shares$12.9▼ 17.31%Market cap $93.65MP/E —$6.79$41.72
- SERASera Prognostics Inc. Class A Common Stock$2.06▲ 1.48%Market cap $78.32MP/E —$1.56$3.95
- XGNExagen Inc. Common Stock$7.72▼ 9.81%Market cap $159.64MP/E —$2.59$12.23
- YDESYD Bio Limited Ordinary Shares$5.92▼ 12.17%Market cap $167.45MP/E —$1.7$22
- MDXHMDxHealth SA Ordinary Shares$0.207▼ 65.73%Market cap $22.50MP/E —$0.4$5.33
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TLSIW TriSalus Life Sciences Inc. Warrant | $101.95M | — | $0.8799 | ▼ 2.23% | $0.4405$1.85 |
| KEQU Kewaunee Scientific Corporation Common Stock | $108.73M | 11.26 | $32.93 | ▲ 2.30% | $32$46.57 |
| BNR Burning Rock Biotech Limited American Depositary Shares | $93.65M | — | $12.9 | ▼ 17.31% | $6.79$41.72 |
| SERA Sera Prognostics Inc. Class A Common Stock | $78.32M | — | $2.06 | ▲ 1.48% | $1.56$3.95 |
| XGN Exagen Inc. Common Stock | $159.64M | — | $7.72 | ▼ 9.81% | $2.59$12.23 |
| YDES YD Bio Limited Ordinary Shares | $167.45M | — | $5.92 | ▼ 12.17% | $1.7$22 |
| MDXH MDxHealth SA Ordinary Shares | $22.50M | — | $0.207 | ▼ 65.73% | $0.4$5.33 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Institutional Ownership
March 31, 2026
- Total shares held
- 1.02M
- Total value held
- $1.15M
- Institutional holders
- 7
- Unknown827.6K
- Unknown70.8K
- Unknown65.2K
- Unknown28.6K
- Unknown26.4K
- Unknown5.2K
- Unknown50
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
TriSalus Warrant Gains After FDA Clears TriNav Advance
TriSalus Life Sciences received FDA clearance for its TriNav Advance device, a move that strengthens its portfolio for liver embolization. This regulatory approval contributed to a 15.6% rise in the company's shares. The positive news provides context for the warrant's recent price action, which remains within its 52-week trading range.
TriSalus Warrant Gains After FDA Clears TriNav Advance. TriSalus Life Sciences received FDA clearance for its TriNav Advance device, a move that strengthens its portfolio for liver embolization. This regulatory approval contributed to a 15.6% rise in the company's shares. The positive news provides context for the warrant's recent price action, which remains within its 52-week trading range.